Nafia Shahid, Iram Jaffri, Afifa Siddiq
Objective: The outcomes were mostly debatable; consequently researchers led the current investigation to decide the suitability of intravenous magnesium sulphate in severe asthma founded on its endpoint. Continued enthusiasm for intravenous magnesium sulfate to use it in many different signs other than controlling eclamptic attacks has led analysts to try it as the smooth muscle relaxant in patients of severe bronchial asthma. Methods: We thoughtfully checked all cases of severe asthma conceded during the review period on the treatment charts and extracted important data. Our current research was conducted at Sir Ganga Ram January 2018 to December 2018. Each of the patients was first treated with standard asthma therapy and then given 4ml of 53% (2g) MgSO4 weakened MgSO4 in 260ml of typical saline solution intravenously. The results were displayed in rate and frequency while the calm age was displayed as ± SD on average. Results: The average age of people was 46.30 ± 21.2 years. Authors had thewoman power in the sample population (62.4%). Patients who were effectively relieved were 34.4% while those who were no longer active were 58.6%. There was no significant gender distinction in result (p > 0.06). Conclusion:Researchersoriginate that intravenous magnesium sulfate was ineffective in counselling casesthrough severe asthma with respect to improving endurance levels. Keywords: Effectiveness; Magnesium Sulphate; Emergency administration; Bronchial asthma.